Skip to main content

Table 5 The incidences of VBIs in different groups by the initial anti-HBs levels of the children

From: A booster hepatitis B vaccine for children with maternal HBsAg positivity before 2 years of age could effectively prevent vaccine breakthrough infections

Initial anti-HBs level (mIU/mL)

Overall

10–99.99

100–999.99

 ≥ 1000

Pa

Overall

     

 Number

454

38

247

169

 

 VBIs, n (%)

31 (6.83%)

6 (15.79%)

20 (8.10%)

5 (2.96%)

0.004

 Overt or occult HBV infection, n (%)

14 (3.08%)

2 (5.26%)

9 (3.64%)

3 (1.78%)

0.324

Nonbooster group

     

 Number

252

16

132

104

 

 VBIs, n (%)

30 (11.90%)

6 (37.50%)

19 (14.39%)

5 (4.95%)

 < 0.001

 Overt or occult HBV infection, n (%)

14 (5.56%)

2 (12.50%)

9 (6.82%)

3 (2.88%)

0.104

Booster group

     

 Number

202

22

115

65

 

 VBIs, n (%)

1 (0.50%)

1 (4.55%)

0

0

0.109

 Overt or occult HBV infection, n (%)

0

0

0

0

  1. aP values represent the significant differences among three different distributions of anti-HBs titres